Menu
GWAS Study

Associations between genetic variations of HLA and IGHV, vaccination schedule, and COVID-19 vaccine immunogenicity.

Ke L, Feng G, Lyu K et al.

41249154 PubMed ID
GWAS Study Type
180580 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KL
Ke L
FG
Feng G
LK
Lyu K
YB
Yin B
FW
Fang W
DQ
Di Q
Chapter II

Abstract

Summary of the research findings

Interindividual genetic variations significantly influenced SARS-CoV-2-specific immunogenicity after vaccination, particularly for human leukocyte antigen (HLA) alleles. However, the mechanisms of different HLA alleles with varying immunogenicity and additional genetic factors related to immunogenicity remained unexplored. This population-based study utilized data of 180,580 vaccinated individuals from the UK Biobank. A genome-wide association study was conducted to identify significant single nucleotide polymorphisms (SNPs) associated with COVID-19 vaccine immunogenicity, identified by immunoglobulin antibody result. We found that SNPs significantly associated with immunogenicity of COVID-19 vaccines were located near the HLA-DQ and IGHV1-69. We further determined HLA-peptide-binding affinities and found that HLA-DQ alleles were significantly associated with immunogenicity due to variations in HLA-peptide binding affinities. Functional genomics data was applied to assess regulatory mechanisms of significant variants near IGHV1-69. Moreover, we employed Mendelian randomization and found that SNPs near IGHV1-69 were associated with immunogenicity by influencing IGHV1-69 expression. Besides, both genetic factors had interactive effects on immunogenicity. These genetic factors modulated the immune response among recipients with different vaccination interval schedules. Furthermore, we observed an interval of five to six weeks that consistently yielded optimal immunogenicity among population, regardless of genetic factors. This study comprehensively demonstrated how interindividual genetic variations affected immunogenicity of COVID-19 vaccines, suggesting the potential for personalized vaccination and administration strategies.

70,490 European ancestry antibody-positive individuals, 110,090 European ancestry antibody-negative individuals

Chapter III

Study Statistics

Key metrics and study information

180580
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.